टेमोज़ोलोमाइड के इंटरैक्शन

TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (टेमोज़ोलोमाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (टेमोज़ोलोमाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (टेमोज़ोलोमाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (टेमोज़ोलोमाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (टेमोज़ोलोमाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (टेमोज़ोलोमाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (टेमोज़ोलोमाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (टेमोज़ोलोमाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

TEMODAR is contraindicated in patients with a history of serious hypersensitivity reactions to: temozolomide or any other ingredients in TEMODAR; and dacarbazine, since both temozolomide and dacarbazine are metabolized to the same active metabolite 5-(3-methyltriazen-1-yl)-imidazole-4-carboxamide. (टेमोज़ोलोमाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)

Pneumocystis Pneumonia (PCP) : Closely monitor all patients, particularly those receiving steroids, for the development of lymphopenia and PCP. (टेमोज़ोलोमाइड लेबल, चेतावनियां और सावधानियां)